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Abstract
Background: The ability to identify individuals at increased risk of developing tuberculosis (TB) has important implications
for public health policy and patient care. We conducted a general population historical cohort study in all Australian States
and Territories to establish the risk of TB arising in people on chronic hemo- or peritoneal dialysis.
Methodology/Principal Findings: Cases of TB disease in patients receiving chronic dialysis were identified by record linkage
using the Australia & New Zealand Dialysis and Transplant Registry (ANZDATA) and State and Territory TB notification
databases 2001 to 2006. Main outcome measure was the relative risk of TB in people on dialysis, adjusted for TB incidence in
country of birth, sex, age and indigenous status. A total of 6,276 cases of active TB were reported among 19,855,283 people
living in Australia between 2001 and 2006. Among 14,506 patients on dialysis, 37 had a notification for TB disease after
commencing dialysis, of whom 28 were culture positive. The incidence of TB was 66.8/100,000/year (95% CI 47.7 to 93.2)
among people on dialysis and 5.7/100,000/year (95% CI 5.5 to 5.8) in the general population. The adjusted relative risk (aRR)
of TB in people on dialysis was 7.8 (95% CI 3.3 to 18.7), and the aRR of culture positive TB was 8.6 (95% CI 3.9 to 19.3).
Conclusions/Significance: Patients on dialysis are at increased risk of TB. The final decision to screen for, and to treat, LTBI in
individual dialysis patients will be influenced by a cumulative assessment of the risk of reactivation of TB and by assessment
of risk factors for adverse effects of treatment.
Citation: Dobler CC, McDonald SP, Marks GB (2011) Risk of Tuberculosis in Dialysis Patients: A Nationwide Cohort Study. PLoS ONE 6(12): e29563. doi:10.1371/
journal.pone.0029563
Editor: Pere-Joan Cardona, Fundacio ´ Institut d’Investigacio ´ en Cie `ncies de la Salut Germans Trias i Pujol. Universitat Auto `noma de Barcelona. CIBERES, Spain
Received July 26, 2011; Accepted November 30, 2011; Published December 27, 2011
Copyright:  2011 Dobler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by a grant from the Sydney South West Research Foundation. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cdobler@med.usyd.edu.au
Introduction
Treatment of latent tuberculosis infection (LTBI) in high risk
groups such as those who are HIV positive or those in whom anti-
TNFa therapy is to be commenced plays an important role in
control of tuberculosis (TB) disease in low-TB incidence settings.
Patients with chronic renal failure are potentially also a high risk
group for TB. Uremia is associated with immunodeficiency caused
by functional abnormalities of neutrophils, reduced T and B cell
function and impaired monocyte and monocyte-derived dendritic
cell function [1,2,3,4,5]. Additionally, poor nutritional status,
vitamin D deficiency and hyperparathyroidism in patients with
chronic kidney disease contribute to impaired immunity [6,7].
An increased risk of TB in dialysis patients was first reported in
1974 [8]. Since then a number of studies have shown that the risk
of TB in patients with chronic renal failure and on dialysis is
significantly increased [9]. However, most of available data comes
from case control studies, many with poorly defined study bases
and hence risk of selection bias as well as unmeasured confounding
[9]. Population-based cohort studies have described relative risks
of TB of 3.4 to 25.3 in dialysis patients compared to the general
population [10,11,12,13]. Although selection bias was less of a
problem in these population-based cohort studies compared to
case-control studies, most made no adjustment, or only very
limited adjustment, for confounders (Table 1).
There is currently no uniform approach to screening of patients
with chronic renal failure who are on dialysis. Some international
guidelines advocate screening patients on dialysis for LTBI [14],
others do not recommend routine assessment for LTBI in this
patient group [15]. In order to inform health policy decisions
about screening for LTBI in potential high risk groups, such as
people on dialysis, robust estimates of the risk of TB are required.
We conducted a nation-wide, general population historical cohort
study to estimate the risk of TB among people on hemo- or
peritoneal dialysis with adjustment for several important, poten-
tially-confounding, risk factors.
Methods
Ethics Statement
The study protocol was approved by the Sydney South West
Area Health Service Human Research Ethics Committee -
Western Zone, the New South Wales Population & Health
Services Research Ethics Committee, the Australian Institute of
Health and Welfare Ethics Committee, the Queensland Health
Research Ethics & Governance Unit, the Department of Human
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Territory Health Human Research Ethics Committee, the
Department of Health Western Australia Human Research Ethics
Committee, the Tasmania Health and Medical Human Research
Ethics Committee, the South Australia Department of Health
Human Research Ethics Committee and the Northern Territory
Human Research Ethics Committee.
The requirement for written or verbal patients’ consent for this
data linkage study was waived by all of the above mentioned ethics
committees based on a combination of the following criteria: The
size of the population, the proportion of individuals who are likely
to have moved or died since the health information was originally
collected, the risk of introducing potential bias into research and
thereby affecting the generalisability and validity of the results, the
risk of creating additional threats to privacy by having to link
information in order to locate and contact individuals to seek their
consent, the difficulty of contacting individuals directly when there
is no exisiting or continual relationship between the organisation
and the individual and the difficulty of contacting individuals
indirectly through public means, such as advertisments or notices.
Only de-identified information was made available to the
researchers.
Setting and study population
The study cohort was all 19.9 million Australian residents in
2006, 14,506 of whom were on chronic hemo- or peritoneal
dialysis (non-transplant recipients). Australia has a low incidence of
TB of 5.4 per 100,000 population, and over 80% of all TB cases
occur in overseas-born people [16].
Description of data sources and data linkage
Australian and New Zealand Dialysis and Transplant
Registry. People on dialysis were identified using the Australian
and New Zealand Dialysis and Transplant (ANZDATA) Registry.
ANZDATA collects information from all renal units in Australia
and New Zealand. Information collected includes, but is not
limited to, primary renal disease, comorbidities, type of dialysis,
transplant date, drug dosages and country of birth. The full data
collection form as well as detailed information on the ANZDATA
registry have been published online [17].
State and Territory TB notification databases. All TB
treatment is provided free-of-charge of State and Territory health
authorities, who also undertake public health action in relation to
each case. Notification of TB to these health authorities is
compulsory as this notification initiates the public health
investigation and action.
We used the State and Territory TB notification databases to
identify patients with TB. All individuals who were notified as a
case of TB disease between January 2001 and December 2006
were included in our analyses. Data on names, date of notification,
date of birth, sex, country of birth, indigenous status and TB
culture results were extracted for this analysis. Diagnosis of TB in
culture negative cases was based on the finding of clinical,
radiological and histological features typical for pulmonary or
extra-pulmonary TB.
Data linkage. People on dialysis who had an episode of
active TB were identified by record linkage using the ANZDATA
and the State and Territory TB notification databases from
January 2001 to December 2006. Probabilistic linkage was
performed by the Cancer and Screening Unit of the Australian
Institute of Health and Welfare (AIHW). They used names as the
primary linkage key with sex and date of birth used for
confirmation or checking. Match files were created containing
only a unique record identifier for both datasets and the record
linkage identifier. From each of the original datasets, analysis files
were created containing the unique record identifier and all the
data fields required for analysis. Each of the analysis files was then
linked to the match files and the record identifiers were removed
from these analysis files. Hence, anonymized linked files were sent
to us for analysis.
Census data for the general population. Aggregate
Census population data for 2006 classified by strata of age
group, country of birth, sex, and indigenous status were obtained
from the Australian Bureau of Statistics. Age was grouped into 5
year age groups and country of birth was aggregated to groupings
of countries with a similar incidence of TB (,10, 10–24, 25–49,
50–99, 100–299, and $300 per 100,000) based on published
World Health Organization data [18].
The term indigenous is used to refer to Australian Aboriginal
and Torres Strait Islander peoples. It is based on responses to an
Australian Bureau of Statistics standard question for Indigenous
identification, which is used in self-enumerated collections as the
Census 2006. [19].
Sample size and study power
The annual incidence of TB in Australia is 5.4 per 100,000 [16].
Hence, over six years, the expected cumulative incidence is 32 per
100,000. The study population is the entire population of
Australia, that is, approximately 20 million people. We estimated
that there were 13,000 persons on dialysis. The study had 80%
power to detect a five-year cumulative incidence .84 per 100,000
in people on dialysis. This represents a detectable relative risk of
Table 1. Population based cohort studies assessing the relative risk of TB in dialysis patients.
Author, year
of publication,
reference Location
Background
TB incidence
100,0000/year
Number
of dialysis
patients
Relative
Risk
(95% CI)
adjusted
Relative
Risk
(95% CI)
potential
confounders
Relative
Risk is
adjusted for
stratification
by
Ahmed et al, 2004, [10] California, USA 11.9 2,809 11.3 (*) not done none none
Chou et al, 2001, [11] Taiwan 71.1 24,553 6.9 (*) not done none gender, age
Simon et al, 1999, [12] New Jersey, USA 10.7–10.8 4,831 6.9 (*) 3.4 (*) age, race none
Chia et al, 1998, [13] British Columbia,
Canada
10.1** 886 * 25.3 (22.9–31.5) age none
*information missing.
**for age 20–60 years.
doi:10.1371/journal.pone.0029563.t001
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expected increase in risk.
Statistical analysis
The relative risk of TB in patients with DM was estimated
using a log-binomial model with correction for overdispersion
and adjustment for TB incidence in country of birth, sex, age
and indigenous status. Aggregate population data for these
covariates were obtained from the Census as described above.
The population attributable fraction was estimated using the
formula: (Pe * (RR21))/((Pe * (RR21)+1) where RR is the
relative risk, estimated as above, and Pe is the proportion of the
population exposed to the risk factor, that is, the prevalence of
chronic dialysis-treated patients in the population [20]. Individ-
ual level data on potential confounders were available for the
dialysis and TB cohorts. For the general population, we used
aggregated data on the prevalence of potential confounders
derived from the census. For this purpose, we obtained a
contingency table from the Australian Bureau of Statistics
containing population numbers cross-classified by all possible
combinations of strata of the covariates listed above. Only cases
of TB that were notified after the commencement of dialysis
were included. The follow-up period started from 1/1/2001 or
the date of commencement of dialysis, whichever was the later
and continued until 31/12/2006 or the date of diagnosis of TB,
whichever was the earlier. TB incidence rates were expressed per
100,000 person years of follow up with asymptotic 95%
confidence intervals [21].
All statistical analyses were carried out using SAS Statistical
Software (Version9.2) (SAS Institute, Cary, NC, USA).
Results
Description of the cohort
During the study period 14,506 patients received dialysis (non-
transplant recipients); the general population comprised
19,855,283 residents of Australia. Characteristics of the dialysis
population, the general population, the TB population and the
dialysis population with TB are shown in table 2. The proportion
of Australian-born people was lower in the dialysis population
compared to the general population. The proportion of dialysis
patients who were born in a country with a TB incidence $25/
100,000 was higher than in the general population. Indigenous
people were over-represented among patients on dialysis com-
pared to the general population; 11% of all patients on dialysis
were indigenous whereas only 2% of the general population were
indigenous.
Incidence of TB
During the study period, there were 6,276 TB notifications in
the whole Australian population of whom 4,423 (70% of all TB
notifications) were culture positive (Table 2). The overall incidence
of TB in the general population over this period was 5.7 per
100,000 per year (95% confidence interval 5.5 to 5.8) and the
incidence of culture positive TB was 4.0 per 100,000 per year
(95% CI 3.9 to 4.1) (Table 3). Among 14,506 patients on dialysis
Table 2. Characteristics of the general population, the dialysis population, the TB population and the TB in dialysis population.
Variable
General population
including people on
dialysis (n=19,855,283)
Dialysis
population
(n=14,506)
TB population
(n=6,276)
TB in dialysis
population, limited
to TB cases after
start of dialysis
(n=37)
Gender, number (%)
Female 10,056,036 (51) 6,158 (42) 3045 (49) 21 (57)
Male 9,799,247 (49) 8,348 (58) 3231 (51) 16 (43)
Age group in years, number (%)
,15 3,937,213 (20) 33 (0) 272 (4) 0
15–34 5,380,655 (27) 440 (3) 2220 (35) 2 (5.4)
35–54 5,700,354 (29) 2,533 (17) 1729 (28) 2 (5.4)
55–74 3,566,112 (18) 6,638 (46) 1176 (19) 21 (56.8)
$75 1,270,949 (6) 4,862 (34) 879 (14) 12(32.4)
Country of origin, number (%)
Australian born 14,072,943 (71) 9,677 (67) 1212 (19) 6 (16)
born overseas 4,416,033 (22) 4,829 (33) 5064 (81) 31 (84)
Unknown 1,366,307 (7) 0 0 0
Indigenous status, number (%)
non-indigenous or not-stated 19,402,435 (98) 12,939 (89) 6072 (97) 32 (86)
Indigenous 452,848 (2) 1,567 (11) 204 (3) 5 (14)
TB incidence in country of birth (per 100,000), No. (%)
,25 16,792,180 (85) 12,933 (89) 1964 (31) 9 (24)
25–99 884,709 (4) 905 (6) 1350 (22) 11 (30)
$100 754,491 (4) 668 (5) 2962 (47) 17 (46)
Unknown 1,423,903 (7) 0 0 0
doi:10.1371/journal.pone.0029563.t002
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commencement of dialysis. Of these, 28 (76%) were culture
positive. Five (14%) occurred in indigenous people. The mean
duration of follow-up was 3.8 years. The overall incidence of TB
among patients on dialysis was 66.8 per 100,000 person-years
(95% CI 47.7 to 93.2) (Table 3) and the incidence of culture
positive TB was 50.6 (95% CI 34.3 to 74.2) per 100,000 person-
years.
Relative risk of TB
The unadjusted relative risk (RR) of TB in people on dialysis
was 17.1 (95% CI 5.7 to 51.4) for all cases and 19.9 (95% CI 7.0 to
56.4) for culture positive cases. In the multivariate analysis we
adjusted for age, TB incidence in country of origin, indigenous
status and sex. The adjusted relative risk (aRR) of TB in people on
dialysis was 7.8 (95% CI 3.3 to 18.7) for all cases and 8.6 (95% CI
3.9 to 19.3) for culture positive cases, respectively.
The population attributable fraction was 0. 3% based on a
dialysis prevalence of 44.7 per 100,000 population in 2006 [17].
Discussion
In this large, population-based cohort study conducted in 19.9
million residents of Australia we found that people on dialysis have
a seven to eight-fold increased risk of developing TB compared
with the general population.
The relative risk of TB among patients on dialysis in our study,
although significantly increased, is at the lower end of the range of
results reported from many of the previously published case-
control studies and comparable to the findings in three out of the
four published population-based cohort studies (Table 1). A review
by Hussein et al. listed 28 studies on TB in dialysis patients which
had relative risks ranging from 6.9 to 52.5 [9]. In population based
cohort studies (Table 1) relative risks were 11.3 and 6.9,
respectively, in two studies that did not adjust for potential
confounders [10,11] and 3.4 and 25.3, respectively, in two studies
that did adjust for some confounding factors [12,13]. Of the
previously published population-based studies, only a US study
from New Jersey adjusted for age and race. In that study, the
adjusted relative risk was 3.4 [12]. In a Canadian study the
incidence of TB in dialysis patients was 25.3 times higher than the
incidence in the general population aged 20 to 60 years [13]. This
restricted age for the reference population was chosen to be similar
to the age range of the dialysis population. However, the estimated
relative risk was not adjusted for TB incidence in country of birth
[13]. As TB incidence in country of birth is an important
confounder for studies of TB that are conducted in low incidence
settings, it is possible that confounding by differences in TB
incidence in country of birth, led to the high relative risk estimate
of 25.3 in the Canadian study.
The incidence of TB increases with age in low incidence
settings, and people on dialysis tend to be older than the general
population. Hence, adjustment for age, as a potential confounder
is important. It has been previously demonstrated in the
ANZDATA population that foreign born people are over-
represented among dialysis patients [22]. This is likely to reflect
differences in the prevalence of diabetes and various forms of
glomerulonephritis among the foreign-born population compared
to the Australian-born population. This study has shown that the
incidence of TB in the country of birth is one of the strongest
predictors of the risk of developing TB. This is because people
born in countries where TB is endemic are more likely to have
LTBI and remain at risk of developing (reactivation) TB. Thus,
not adjusting for country of birth will result in overestimation of
the relative risk of TB among people on dialysis. This adjustment is
especially important for low TB incidence settings, where the
majority of TB cases usually occur in foreign-born people [23].
HIV is a well known risk factor for TB but the prevalence of
HIV infection is low in Australia [24] and HIV-TB co-infection is
probably uncommon [25]. However, it is acknowledged that HIV
status was reported for only 35% of all Australian TB cases in 2006
[25]. The relatively low prevalence of HIV infection among
migrants from countries with a high domestic prevalence of HIV
infection is probably explained by the ‘‘healthy migrant effect’’
Table 3. Incidence of tuberculosis in the general population and in people on dialysis.
Incidence of all TB
per 100,000/year
(95% confidence interval)
Incidence of culture positive TB
per 100,000/year
(95% confidence interval)
General population People on dialysis General population People on dialysis
All persons 5.7 (5.5 to 5.8) 66.8 (47.7 to 93.2) 4.0 (3.9 to 4.1) 50.6 (34.3 to 74.2)
Age, years
,15 1.2 (1.1 to 1.4) 0 0.4 (0.3 to 0.5) 0
15 to 34 7.4 (7.1 to 7.7) 163.3 (28.3 to 656.2) 5.5 (5.2 to 5.8) 81.6 (4.3 to 528.5)
35 to 54 5.5 (5.2 to 5.7) 24.3 (4.2 to 98.1) 3.9 (3.7 to 4.1) 12.2 (0.6 to 79.0)
55 to 74 6.0 (5.6 to 6.3) 88.5 (56.2 to 137.8) 4.1 (3.8 to 4.4) 67.4 (39.9 to 112.1)
$75 13.0 (12.1 to 13.9) 59.9 (32.5 to 107.8) 9.7 (9.0 to 10.5) 49.9 (25.4 to 95.1)
Sex
Male 5.9 (5.7 to 6.2) 51.0 (30.2 to 84.9) 4.3 (4.1 to 4.5) 35.1 (18.5 to 64.9)
Female 5.4 (5.2 to 5.6) 87.5 (55.6 to 136.2) 3.7 (3.6 to 4.9) 70.8 (42.6 to 116.0)
TB incidence in country of birth
,25 per 100,000 1.95 (1.86 to 2.04) 18.2 (8.9 to 36.0) 1.26 (1.20 to 1.34) 14.2 (6.2 to 30.6)
25–99 per 100,000 25.5 (24.1 to 26.9) 315 (166 to 582) 18.0 (16.9 to 19.2) 258 (126 to 508)
$100 per 100,000 65.4 (63.1 to 67.8) 698 (420 to 1140) 48.8 (46.8 to 50.9) 493 (267 to 885)
doi:10.1371/journal.pone.0029563.t003
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visa application process. Dialysis patients are routinely screened
for HIV, but this information is not systematically collected in
ANZDATA. It is possible that a higher prevalence of HIV
infection among the dialysis cohort could have contributed to the
increased TB risk. However, rates of HIV nephropathy (reported
as the primary cause of end-stage kidney failure) are extremely low
in Australia [17]. HIV infection thus is an unlikely to be an
important confounder in the between dialysis status and TB
disease in Australia.
Our study included patients on hemodialysis as well as patients
on peritoneal dialysis. Patients on hemodialysis and peritoneal
dialysis share the same risks associated with acquired immunode-
ficiency due to uraemia. A Chinese study that examined the risk of
TB in 790 patients undergoing continuous ambulatory peritoneal
dialysis found a RR of 7 in this group compared to the general
population [27]. This result would be in keeping with the range of
RRs reported in studies of patients on hemodialysis.
Major strengths of our study are the large size and the general
population-based nature of the cohort. This has resulted in
estimates that are both reliable and generalisable. A limitation
that this study shares with previously published papers in this
area is that we did not have any information on treatment of
LTBI in the dialysis cohort. Routine assessment and treatment
f o rL T B Ii nd i a l y s i sp a t i e n t si sc u r r e n t l yn o tr e c o m m e n d e di n
Australia, and it can therefore be assumed that most patients on
dialysis would not have been assessed and treated for LTBI.
However, it is possible that some renal physicians and renal units
would have screened and treated dialysis patients for LTBI, thus
lowering the risk in this cohort of developing active TB. While
screening of dialysis patients for latent TB infection is not
standard practice in Australia, patients with chronic renal failure
awaiting renal transplantation are commonly screened and
treated for LTBI before going on a renal transplant waiting list.
For this reason we did not include data on renal transplant
patients that were also available from ANZDATA in this study,
as the true risk of developing TB likely would have been
underestimated.
Other conditions known to be associated with an increased risk
of TB include TNFalpha-blocker therapy [28] and being a close
contact of a patient with active TB [29]. People in these groups,
along with HIV positive individuals, are routinely screened for
LTBI in low TB-incidence settings. We have shown here that
dialysis patients do have a substantially increased risk of TB
compared to the general population, although the increase is not
as great as for HIV positive status, TNFalpha blocker therapy or a
history of recent TB contact. While our study provides important
information to inform the public health and clinical decision
making process about LTBI screening in patients on dialysis, it was
not designed to evaluate the overall benefit of LTBI screening
among dialysis patients. Further studies are required to examine
the effectiveness and cost-effectiveness of such an intervention.
This study confirms that the risk of TB in dialysis patients is
substantially increased. The absolute risk of TB in dialysis patients
without other risk factors for TB may not be sufficiently high to
warrant screening for LTBI. However, in dialysis patients with
additional risk factors, especially in those who were born in TB
endemic countries, screening for, and treatment of, LTBI should
be considered. Further studies are required to investigate the cost-
effectiveness of such an intervention. The final decision to treat
LTBI in individual patients will be influenced, on the one hand, by
factors associated with risk of adverse effects of treatment, such as
age and co-morbid liver disease, and on the other hand by
additional factors affecting the cumulative risk of reactivation of
TB including life-expectancy and the presence of other co-morbid
conditions.
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